Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 901–1,000 of 1,008
Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
Filippi, M., Balestrino, R., Basaia, S., & Agosta, F. (2022) · Movement Disorders · doi:10.1002/mds.29047 · Cited by 29
LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
Galper, J., Kim, W. S., & Dzamko, N. L. (2022) · Biomolecules · doi:10.3390/biom12111597 · Cited by 30
Grigor’eva, E. V., Kopytova, A. E., Yarkova, E. S., Pavlova, S. V., Sorogina, D. A., Malakhova, A. A., Malankhanova, T. B., Baydakova, G., Zakharova, E. Y., Medvedev, S. P., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054437 · Cited by 32
“It is known that, in PD, the frequency of GBA mutations reaches 10%, while the risk of PD development among individuals carrying GBA mutations increases up to 20 times based on ethnicity [3,4].”
BackgroundLysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease
Tunold, J., Tan, M. M. X., Koga, S., Geut, H., Rozemüller, A. J. M., Valentino, R. R., Sekiya, H., Martin, N. B., Heckman, M. G., Brás, J., et al. (2023) · Brain · doi:10.1093/brain/awad183 · Cited by 32
Single-Cell Sequencing in Neurodegenerative Disorders
Pozojevic, J., & Spielmann, M. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00668-9 · Cited by 30
The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson’s therapeutics
Rubilar, J. C., Outeiro, T. F., & Klein, A. D. (2024) · Brain · doi:10.1093/brain/awae070 · Cited by 31
Candidate genes for Parkinson disease: Lessons from pathogenesis
Rosa, P. D., Marini, E. S., Gelmetti, V., & Valente, E. M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.042 · Cited by 32
Weiß, D., Brockmann, K., Srulijes, K., Meisner, C., Klotz, R., Reinbold, S., Hauser, A., Schulte, C., Berg, D., Gasser, T., et al. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6469-7 · Cited by 29
Self-citationTranscranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease
Barrett, M. J., Hagenah, J., DHAWAN, V. M., Peng, S., Stanley, K. M., Raymond, D., Deik, A., Gross, S. J., Schreiber‐Agus, N., Mirelman, A., et al. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.09.007 · Cited by 30
Self-citationSanders, A., Hemmelgarn, H., Melrose, H. L., Hein, L. K., Fuller, M., & Clarke, L. A. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.03.006 · Cited by 30
“alleles in the pathogenesis of Parkinson disease [4,5].”
BackgroundKnight, E. M., Williams, H. N., Stevens, A. C., Kim, S. H., Kottwitz, J., Morant, A., Steele, J., Klein, W. L., Yanagisawa, K., BOYD, R. E., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.135 · Cited by 32
Lupus: How much “complexity” is really (just) genetic heterogeneity?
Crow, Y. J. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30603 · Cited by 31
Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging
Argyriou, A., Dermentzaki, G., Papasilekas, T., Moraitou, M., Stamboulis, E., Vekrellis, K., Michelakakis, H., & Stefanis, L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.08.069 · Cited by 32
Bendikov-Bar, I., Rapaport, D., Larisch, S., & Horowitz, M. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-86 · Cited by 29
Innate immune responses in the brain of sphingolipid lysosomal storage diseases
Vitner, E. B., Futerman, A. H., & Platt, N. (2015) · Biological Chemistry · doi:10.1515/hsz-2014-0301 · Cited by 30
“Carrying a mutation in GBA is the highest risk factor for the development of Parkinson’s disease and Lewy body dementia (Sidransky et al., 2009).”
BackgroundLysosomal Proteins as a Therapeutic Target in Neurodegeneration
Donald, J. M. M., & Krainc, D. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104432 · Cited by 31
Doppler, K., Brockmann, K., Sedghi, A., Wurster, I., Volkmann, J., Oertel, W. H., & Sommer, C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01094 · Cited by 31
Choi, J.-M., Hong, J.-H., Chae, M.-J., Hung, N. P., Kang, H.-S., Ma, H., & Kim, Y. J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.02.013 · Cited by 31
How neurons maintain their axons long-term: an integrated view of axon biology and pathology
Smith, G. A., Sweeney, S. T., O’Kane, C. J., & Prokop, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1236815 · Cited by 29
“, 2021), or by mutation of β-glucosidase linked to Gaucher disease (‘GBA’ in Supplementary Table S1) and PARK9 (Sidransky et al., 2009; Zigdon et al., 2017; Berge-Seidl and Toft, 2020).”
BackgroundConvergent pathways in Parkinson’s disease
Cherubini, M., & Wade‐Martins, R. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2700-2 · Cited by 31
“GCase is a lysosomal enzyme encoded by the GBA gene and mutations are recognized as an important genetic risk factor for the development of PD (Sidransky et al. 2009).”
BackgroundMa, G., Liu, H., Du, M., Zhang, G., Lin, Y., Ge, Y., Wang, M., Jin, G., Zhao, Q., Chu, H., et al. (2019) · Cancer · doi:10.1002/cncr.32081 · Cited by 29
“43-fold higher risk of developing Parkinson disease than the control population, indicating that GBA mutations are also a high-risk risk factor for Parkinson disease.(36) The mechanism of GBA involvement in tumorigenesis and development has rarely been reported.”
BackgroundGenetic causes of PD: A pathway to disease modification
Toffoli, M., Vieira, S. R. L., & Schapira, A. H. V. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108022 · Cited by 29
Structure, metabolism and biological functions of steryl glycosides in mammals
Shimamura, M. (2020) · Biochemical Journal · doi:10.1042/bcj20200532 · Cited by 28
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms
Wildburger, N. C., Hartke, A.-S., Schidlitzki, A., & Richter, F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.598446 · Cited by 30
Motyl, J. A., Strosznajder, J. B., Wencel, A., & Strosznajder, R. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126277 · Cited by 29
Cognitive Impairment in Genetic Parkinson’s Disease
Planas-Ballvé, A., & Vilas, D. (2021) · Parkinson s Disease · doi:10.1155/2021/8610285 · Cited by 32
“A multicenter study identified GBA mutations in 3% of PD patients and found that GBA mutations increase the risk of PD by approximately fivefold [78].”
BackgroundInfluentialSkin alpha-synuclein deposit patterns: A predictor of Parkinson's disease subtypes
Han, Y., Wu, D., Wang, Y., Xie, J. M., & Zhang, Z. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104076 · Cited by 30
Mahoney-Crane, C. L., Viswanathan, M., Russell, D. L., Curtiss, R. A. C., Freire, J., Bobba, S. S., Coyle, S. D., Kandebo, M., Yao, L., Wan, B.-L., et al. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0680-22.2022 · Cited by 33
Belur, N. R., Bustos, B. I., Lubbe, S. J., & Mazzulli, J. R. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.003 · Cited by 31
A nonsynonymous variant of IL1A is associated with endometriosis in Japanese population
Hata, Y., Nakaoka, H., Yoshihara, K., Adachi, S., Haino, K., Yamaguchi, M., Nishikawa, N., Kashima, K., Yahata, T., Tajima, A., et al. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.32 · Cited by 30
Franco, R., Sánchez-Arias, J. A., Navarro, G., & Lanciego, J. L. (2018) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2018.00052 · Cited by 30
Non-cell-autonomous actions of α-synuclein: Implications in glial synucleinopathies
Lim, S., Kim, H., Kim, D., & Lee, S. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.06.010 · Cited by 29
Thomas, R., Moloney, E. B., Macbain, Z. K., Hallett, P. J., & Isacson, O. (2021) · Molecular Brain · doi:10.1186/s13041-020-00712-3 · Cited by 30
Role of GBA variants in Lewy body disease neuropathology
Walton, R. L., Koga, S., Soto‐Beasley, A. I., White, L. J., Griesacker, T., Murray, M. E., Kasanuki, K., Hou, X., Fiesel, F. C., Springer, W., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02699-w · Cited by 32
A Global Perspective of GBA1-Related Parkinson’s Disease: A Narrative Review
Koros, C., Bougea, A. M., Alefanti, I., Simitsi, A., Papagiannakis, N., Pachi, I., Sfikas, E., Antonelou, R. C., & Stefanis, L. (2024) · Genes · doi:10.3390/genes15121605 · Cited by 30
Han, F., Grimes, D. A., Li, F., Wang, T., Yu, Z., Song, N., Wu, S., Racacho, L., & Bulman, D. E. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1023436 · Cited by 29
Genomic aspects of sporadic neurodegenerative diseases
Mitsui, J., & Tsuji, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.098 · Cited by 31
Self-citationProgress toward an integrated understanding of Parkinson’s disease
Rousseaux, M. W. C., Shulman, J. M., & Jankovic, J. J. (2017) · F1000Research · doi:10.12688/f1000research.11820.1 · Cited by 30
Overview of Inflammation in Neurometabolic Diseases
Grabowski, G. A. (2017) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2017.08.005 · Cited by 29
Leucine‐rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease
Cogo, S., Manzoni, C., Lewis, P. A., & Greggio, E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14908 · Cited by 27
“GBA1 encodes a lysosomal enzyme with an essential role in glycolipid metabolism and heterozygous coding mutations represent the most prevalent risk factor for PD (Sidransky et al. 2009).”
BackgroundGBA variation and susceptibility to multiple system atrophy
Wernick, A. I., Walton, R. L., Koga, S., Soto‐Beasley, A. I., Heckman, M. G., Gan‐Or, Z., Ren, Y., Rademakers, R., Uitti, R. J., Wszołek, Z. K., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.06.007 · Cited by 28
Self-citationProfiling Non-motor Symptoms in Monogenic Parkinson’s Disease
Liu, X., & Le, W. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.591183 · Cited by 31
Yu, W. H., Ying, J., Wang, X., Liu, X., Zhao, T., Yoon, S., Zheng, Q., Fang, Y., Yang, D., & Hua, F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.691230 · Cited by 30
Zhao, Y., Pan, H.-X., Liu, Z., Wang, Y., Zeng, Q., Fang, Z., Luo, T., Xu, K., Wang, Z., Zhou, X. C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.749109 · Cited by 31
“Heterozygous, homozygous, or compound heterozygous mutations in the GBA gene have been robustly confirmed as the most important genetic risk factor for PD, increasing the risk of PD by more than five times (Sidransky et al., 2009; Chahine et al., 2013).”
BackgroundSelf-citationPollmanns, M. R., Beer, J., Rosignol, I., Rodríguez‐Muela, N., Falkenburger, B. H., & Dinter, E. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.861202 · Cited by 33
Palomba, N. P., Fortunato, G., Pepe, G., Modugno, N., Pietracupa, S., Damiano, I., Mascio, G., Carrillo, F., Giovannantonio, L. G. D., Ianiro, L., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03203-9 · Cited by 30
Sphingolipids and impaired hypoxic stress responses in Huntington disease
Burtscher, J., Pepe, G., Maharjan, N., Riguet, N., Pardo, A. D., Maglione, V., & Millet, G. P. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101224 · Cited by 28
Pachchek, S., Landoulsi, Z., Pavelka, L., Schulte, C., Buena‐Atienza, E., Groß, C., Hauser, A., Bobbili, D. R., Casadei, N., May, P., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00595-w · Cited by 37
Self-citationFactors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
Persichetti, E., Chiasserini, D., Parnetti, L., Eusebi, P., Paciotti, S., Carlo, C. D., Codini, M., Tambasco, N., Rossi, A., El‐Agnaf, O. M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101453 · Cited by 29
Genetics of Parkinson’s Disease - A Clinical Perspective
Cheon, S., Chan, L., Chan, D. K. Y., & Kim, J. W. (2012) · Journal of Movement Disorders · doi:10.14802/jmd.12009 · Cited by 31
Gupte, M., Alcalay, R. N., Mejia‐Santana, H., Raymond, D., Saunders-Pullman, R. J., Roos, E., Orbe‐Reilly, M., Tang, M., Mirelman, A., Ozelius, L. J., et al. (2014) · Journal of Genetic Counseling · doi:10.1007/s10897-014-9756-x · Cited by 27
Self-citationWestbroek, W., Nguyen, M. H., Siebert, M., Lindstrom, T., Burnett, R. A., Aflaki, E., Jung, O., Tamargo, R. J., Rodriguez‐Gil, J. L., Acosta, W. L., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024588 · Cited by 29
“Mutations in GBA1 have now been established as an important risk factor for the development of synucleinopathies including Parkinson disease (PD) (Sidransky et al., 2009), dementia with Lewy bodies (DLB) (Nalls et al., 2013), and multiple system atrophy (MSA) (Mitsui et al., 2015).”
Self-citationInduced pluripotent stem cell-based modeling of neurodegenerative diseases: a focus on autophagy
Jungverdorben, J., Till, A., & Brüstle, O. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1533-5 · Cited by 29
Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder
Gámez‐Valero, A., Iranzo, Á., Serradell, M., Vilas, D., Santamaría, J., Gaig, C., Álvarez, R., Ariza, A., TOLOSA, E. S., & Beyer, K. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.034 · Cited by 28
Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase
Zheng, J., Jeon, S., Jiang, W., Burbulla, L. F., Ysselstein, D., Oevel, K., Krainc, D., & Silverman, R. B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01294 · Cited by 28
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review
Gaubert, S., Hourregue, C., Mouton-Liger, F., Millot, P., Franco, M., Amar-Bouaziz, E., Aarsland, D., Hugon, J., & Paquet, C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104856 · Cited by 26
“Furthermore, the strong association between GBA1 mutations and DLB (OR: 8.28) was higher than reported in PD (OR: 5.43) and in PD with dementia (OR: 6.48) (Sidransky et al., 2009; Nalls et al., 2013).”
BackgroundInfluentialVitola, P. L., Szegő, É. M., Pinto‐Costa, R., Rollar, A., Harbachova, E. L., Schapira, A. H. V., Ulusoy, A., & Monte, D. A. D. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00842-8 · Cited by 29
Machaczka, M., Paucar, M., Björkvall, C. K., Smith, N. J. C., Cox, T. M., Forsgren, L., & Svenningsson, P. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.10.011 · Cited by 27
New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics
Sardi, S. P., & Simuni, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.025 · Cited by 28
Membrane Interactions of α-Synuclein Probed by Neutrons and Photons
Kaur, U., & Lee, J. C. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00453 · Cited by 28
Zheng, W., & Fan, D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.851135 · Cited by 28
What have we learned from genome-wide association studies (GWAS) in Parkinson's disease?
Fernández‐Santiago, R., & Sharma, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101648 · Cited by 28
Self-citationWho Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α‐Synuclein
Jensen, P. H., Schlossmacher, M. G., & Stefanis, L. (2023) · Movement Disorders · doi:10.1002/mds.29318 · Cited by 26
Laboratory and genetic evaluation of Gaucher disease
Bodamer, O. A., & Hung, C. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0814-1 · Cited by 26
Prevalence and management of Gaucher disease
Grabowski, G., Barnes, & Burrow (2011) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s12499 · Cited by 26
The LIMP-2/SCARB2 Binding Motif on Acid β-Glucosidase
Liou, B., Haffey, W. D., Greis, K. D., & Grabowski, G. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.593616 · Cited by 31
Genetic Convergence of Parkinson’s Disease and Lysosomal Storage Disorders
Deng, H., Xiu, X., & Jankovic, J. J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8832-4 · Cited by 32
Impaired gait kinematics in type 1 Gaucher’s Disease
Sorrentino, P., Barbato, A., Gaudio, L. D., Rucco, R., Varriale, P., Sibilio, M., Strazzullo, P., Sorrentino, G., & Agosti, V. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150660 · Cited by 26
Analysis of age-related changes in psychosine metabolism in the human brain
Marshall, M. S., Jakubauskas, B., Bogue, W., Stoskute, M., Hauck, Z., Rue, E. A., Nichols, M., DiAntonio, L. L., van Breemen, R. B., Kordower, J. H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193438 · Cited by 27
Dung, V. M., & Thảo, Đ. T. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0529-0_4 · Cited by 28
Sequencing of the GBA coactivator, Saposin C, in Parkinson disease
Bencheikh, B. O. A., Léveillé, E., Ruskey, J. A., Spiegelman, D., Liong, C., Fon, E. A., Rouleau, G. A., Dauvilliers, Y. A., Dupré, N., Alcalay, R. N., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.034 · Cited by 29
Self-citationMishra, A., Chandravanshi, L. P., Trigun, S. K., & Krishnamurthy, S. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.028 · Cited by 28
Gaucher Disease: New Expanded Classification Emphasizing Neurological Features.
Alaei, M. R., Tabrizi, A., Jafari, N., & Mozafari, H. (2019) · Iranian journal of child neurology. · doi:10.22037/ijcn.v13i1.21757 · Cited by 40
‘Atypical’ Parkinson's disease – genetic
Weißbach, A., Wittke, C., Kasten, M., & Klein, C. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.011 · Cited by 28
Fabry Disease With Concomitant Lewy Body Disease
Tredici, K. D., Ludolph, A. C., Feldengut, S., Jacob, C., Reichmann, H., Böhl, J., & Braak, H. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz139 · Cited by 26
Niimi, Y., Mizutani, Y., Akiyama, H., Watanabe, H., Shiroki, R., Hirabayashi, Y., Hoshinaga, K., & Mutoh, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202310 · Cited by 26
African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1
Jerez, P. Á., Crea, P. W., Ramos, D. M., Gustavsson, E. K., Radefeldt, M., Damianov, A., Makarious, M. B., Ojo, O. O., Billingsley, K. J., Malik, L., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01423-2 · Cited by 29
Self-citationGan‐Or, Z., Bar‐Shira, A., Gurevich, T., Giladi, N., & Orr‐Urtreger, A. (2011) · Neurogenetics · doi:10.1007/s10048-011-0293-6 · Cited by 26
“A very strong association has been established between heterozygous GBA mutations and Parkinson's disease (PD [MIM# 168600]) in a number of populations [1–10], and a large multi-center analysis further highlighted the importance of these mutations as risk factors for the development of PD worldwide [11].”
BackgroundSelf-citationFarotti, L., Paciotti, S., Tasegian, A., Eusebi, P., & Parnetti, L. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1341312 · Cited by 26
Patient's perception: shorter and more severe prodromal phase in GBA ‐associated PD
Zimmermann, M., Gaenslen, A., Prahl, K., Srulijes, K., Hauser, A., Schulte, C., Csóti, I., Berg, D., & Brockmann, K. (2018) · European Journal of Neurology · doi:10.1111/ene.13776 · Cited by 25
“Heterozygous mutations in the GBA gene represent the most common genetic risk factor for PD [2].”
BackgroundSelf-citationCoding variation in GBA explains the majority of the SYT11‐GBA Parkinson's disease GWAS locus
Blauwendraat, C., Brás, J., Nalls, M. A., Lewis, P. A., Hernandez, D. G., & Singleton, A. (2018) · Movement Disorders · doi:10.1002/mds.103 · Cited by 25
“Unfortunately, another relatively common disease associated, L483P, could not be genotyped.(1) Interestingly, variant p.”
BackgroundSelf-citationUsenko, T. S., Bezrukova, A. I., Basharova, K. S., Panteleeva, A., Nikolaev, M. A., Kopytova, A. E., Miliukhina, I. V., Emelyanov, A., Zakharova, E. Y., & Pchelina, S. (2021) · Genes · doi:10.3390/genes12101545 · Cited by 27
Hurben, A. K., & Tretyakova, N. Y. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00193 · Cited by 26
Ortega, R. A., Bressman, S., Raymond, D., Ozelius, L. J., Katsnelson, V., Leaver, K. R., Swan, M. C., Shanker, V., Miravite, J., Wang, C., et al. (2022) · Movement Disorders · doi:10.1002/mds.29197 · Cited by 26
“European cohorts are more likely to have a greater proportion of severe variant carriers than, for example, Ashkenazi Jewish cohorts in whom the mild variants are most frequent.(42,43) GBA screening methodologies, notoriously difficult because of a pseudogene, have changed over time, as has our knowledge of variants c…”
BackgroundThe genetic basis of multiple system atrophy
Tseng, F. S., Foo, J. Q. X., Mai, A. S., & Tan, E. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03905-1 · Cited by 29
Self-citationGenetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview
Yahya, V., Fonzo, A. D., & Monfrini, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076338 · Cited by 27
Asimakidou, E., Xiromerisiou, G., & Sidiropoulos, C. (2024) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13994 · Cited by 27
Current trends in basic research on Parkinson’s disease: from mitochondria, lysosome to α-synuclein
Matsui, H., & Takahashi, R. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02774-2 · Cited by 27
Lipid accumulation drives cellular senescence in dopaminergic neurons
Russo, T., & Rießland, M. (2024) · Aging · doi:10.18632/aging.206030 · Cited by 27
From rare to common and back again: 60years of lysosomal dysfunction
Coutinho, M. F., & Alves, S. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.08.008 · Cited by 30
Greater risk of parkinsonism associated with non‐N370S GBA1 mutations
Barrett, M. J., Giraldo, P., Capablo, J. L., Alfonso, P., Irún, P., Garcia‐Rodriguez, B., Pocoví, M., & Pastores, G. M. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9527-5 · Cited by 26
Puschmann, A., Brighina, L., Markopoulou, K., Aasly, J. O., Chung, S. J., Frigerio, R., Hadjigeorgiou, G. M., Kõks, S., Krüger, R., Siuda, J. S., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.04.029 · Cited by 25
Self-citationGaucher-Associated Parkinsonism
Li, Y., Li, P., Liang, H., Zhao, Z., Hashimoto, M., & Wei, J. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0176-8 · Cited by 26
Multiple system atrophy: the application of genetics in understanding etiology
Federoff, M., Schottlaender, L., Houlden, H., & Singleton, A. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0267-5 · Cited by 26
Self-citationMutations in Niemann Pick type C gene are risk factor for Alzheimer’s disease
Kresojević, N. D., Dobričić, V., Svetel, M. V., & Kostić, V. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.08.025 · Cited by 28
Chen, M., Yang, W., Li, X., Li, X., Wang, P., Yue, F., Yang, H., Chan, P., & Yu, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6445 · Cited by 34
Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease
da Silva, C. P., Abreu, G. D. M., Cabello, P. H., Campos, M., Pereira, J. S., Ramos, S. R. D. A., Nascimento, C. M., Voigt, D. D., de Rosso, A. L. Z., Leite, M. A. A., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3249 · Cited by 27
Genetic risk factors in Finnish patients with Parkinson's disease
Ylönen, S., Siitonen, A., Nalls, M. A., Ylikotila, P., Autere, J. M., Eerola‐Rautio, J., Gibbs, J. R., Hiltunen, M., Tienari, P., Soininen, H. S., et al. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.09.021 · Cited by 25
Self-citationParkinson's Disease: Patients’ Knowledge, Attitudes, and Interest in Genetic Counseling
Maloney, K. A., Alaeddin, D. S., von Coelln, R., Dixon, S., Shulman, L. M., Schrader, K., & Guan, Y. (2018) · Journal of Genetic Counseling · doi:10.1007/s10897-018-0239-3 · Cited by 26
“Heterozygous carriers of mutations in the glucocerebrosidase gene (GBA), that cause Gaucher disease in the homozygous state, have a five-fold increased risk for PD, making it the strongest genetic risk factor identified to date (Sidransky et al. 2009).”
Background
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.